NCT01704716 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT01704716
Title	High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	St. Anna Kinderkrebsforschung
Indications	neuroblastoma
Therapies	Busulfan + Melphalan Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Filgrastim Cisplatin + Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Sulfate Dinutuximab beta Aldesleukin + Dinutuximab beta Carboplatin + Etoposide + Melphalan Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate
Age Groups:	child \| adult
Covered Countries	SWE \| SVN \| SVK \| POL \| NOR \| ITA \| ISR \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| CZE \| CHE \| BEL \| AUT \| AUS

No variant requirements are available.